This interactive workshop will explore best practices to reach and finalize settlements that the parties and the FTC can live with. Points of discussion will include:

THE INDUSTRY VIEW

  • Exploring your settlement options
  • Which settlements have received approval and which have not?
  • The role of authorized generics in settlement agreements
  • Strategies to employ pending completion of the FTC's review

THE FTC'S POSITION

  • FTC enforcement actions against anticompetitive agreements between brand-name and generic drug manufacturers
  • The Commission's study of the competitive impact of authorized generic drugs and their role in settlement negotiations
  • The implications of Hatch-Waxman reforms under the MMA on competition in the pharmaceutical industry
  • FTC's amicus brief and citizen petition filings on this subject